Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
Top Cited Papers
Open Access
- 4 September 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (2), 163-171
- https://doi.org/10.1093/cid/cix783
Abstract
The efficacy of ceftazidime-avibactam—a cephalosporin–β-lactamase inhibitor combination with in vitro activity against Klebsiella pneumoniae carbapenemase–producing carbapenem-resistant Enterobacteriaceae (CRE)—compared with colistin remains unknown. Patients initially treated with either ceftazidime-avibactam or colistin for CRE infections were selected from the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), a prospective, multicenter, observational study. Efficacy, safety, and benefit-risk analyses were performed using intent-to-treat analyses with partial credit and the desirability of outcome ranking approaches. The ordinal efficacy outcome was based on disposition at day 30 after starting treatment (home vs not home but not observed to die in the hospital vs hospital death). All analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW). Thirty-eight patients were treated first with ceftazidime-avibactam and 99 with colistin. Most patients received additional anti-CRE agents as part of their treatment. Bloodstream (n = 63; 46%) and respiratory (n = 30; 22%) infections were most common. In patients treated with ceftazidime-avibactam versus colistin, IPTW-adjusted all-cause hospital mortality 30 days after starting treatment was 9% versus 32%, respectively (difference, 23%; 95% bootstrap confidence interval, 9%–35%; P = .001). In an analysis of disposition at 30 days, patients treated with ceftazidime-avibactam, compared with those treated within colistin, had an IPTW-adjusted probability of a better outcome of 64% (95% confidence interval, 57%-71%). Partial credit analyses indicated uniform superiority of ceftazidime-avibactam to colistin. Ceftazidime-avibactam may be a reasonable alternative to colistin in the treatment of K. pneumoniae carbapenemase–producing CRE infections. These findings require confirmation in a randomized controlled trial.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (UM1AI104681, R21AI114508)
This publication has 29 references indexed in Scilit:
- Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyThe Lancet Infectious Diseases, 2015
- Comment: Fundamentals and Innovation in Antibiotic TrialsStatistics in Biopharmaceutical Research, 2015
- Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)Clinical Infectious Diseases, 2015
- Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistanceClinical Microbiology & Infection, 2014
- Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional NetworkAntimicrobial Agents and Chemotherapy, 2014
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesThe Lancet Infectious Diseases, 2013
- Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesDiagnostic Microbiology and Infectious Disease, 2013
- "Silent" Dissemination of Klebsiella pneumoniae Isolates Bearing K. pneumoniae Carbapenemase in a Long-term Care Facility for Children and Young Adults in Northeast OhioClinical Infectious Diseases, 2012
- Increasing prevalence and dissemination of NDM-1 metallo- -lactamase in India: data from the SMART study (2009)Journal of Antimicrobial Chemotherapy, 2011
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987